27,441 Merck & Co., Inc. $MRK Shares Purchased by Vestor Capital LLC

Vestor Capital LLC increased its stake in Merck & Co., Inc. (NYSE:MRK) by 16,530.7% in the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 27,607 shares of the company’s stock after acquiring an additional 27,441 shares during the period. Vestor Capital LLC’s holdings in Merck & Co., Inc. were worth $4,012,000 as of its most recent SEC filing.

Several other large investors also recently added to or reduced their stakes in MRK. Kestra Investment Management LLC raised its position in Merck & Co., Inc. by 6.9% during the third quarter. Kestra Investment Management LLC now owns 17,594 shares of the company’s stock valued at $2,557,000 after purchasing an additional 1,130 shares during the period. Leuthold Group LLC lifted its stake in shares of Merck & Co., Inc. by 9.5% in the 3rd quarter. Leuthold Group LLC now owns 52,353 shares of the company’s stock valued at $7,607,000 after purchasing an additional 4,550 shares during the last quarter. Clear Wave Wealth Management LLC lifted its stake in shares of Merck & Co., Inc. by 39.9% in the 3rd quarter. Clear Wave Wealth Management LLC now owns 8,786 shares of the company’s stock valued at $1,277,000 after purchasing an additional 2,506 shares during the last quarter. Kohmann Bosshard Financial Services LLC boosted its holdings in shares of Merck & Co., Inc. by 37.6% in the 3rd quarter. Kohmann Bosshard Financial Services LLC now owns 2,838 shares of the company’s stock worth $412,000 after purchasing an additional 776 shares during the period. Finally, Joseph Group Capital Management boosted its holdings in shares of Merck & Co., Inc. by 29.1% in the 3rd quarter. Joseph Group Capital Management now owns 780 shares of the company’s stock worth $113,000 after purchasing an additional 176 shares during the period. 76.07% of the stock is owned by institutional investors.

Key Merck & Co., Inc. News

Here are the key news stories impacting Merck & Co., Inc. this week:

• Positive Sentiment: Merck reported positive Phase 2b results for efinopegdutide, an investigational weekly treatment for adults with MASH and stage F2 or F3 liver fibrosis. The findings add a potential new opportunity in liver disease, although the supplied report does not include detailed efficacy results. Article: Merck Announces Positive Results from Phase 2b Trial of Efinopegdutide
• Positive Sentiment: Merck has started the Phase 3 ENHANCE-3 trial of OHTUVAYRE for COPD maintenance treatment. Separately, the FDA granted priority review to sacituzumab tirumotecan for endometrial cancer, advancing two potential growth drivers. Article: Merck Starts ENHANCE 3 COPD Trial As Cancer Drug Review Nears
• Neutral Sentiment: Merck’s collaboration with Tempus AI is expected to contribute to a five-year partnership value of roughly $192.5 million, providing a data and AI-related research tie-up; the article does not detail the financial impact to Merck. Article: The AI Debt Bill Is Coming Due, But Biotech Has Revenue to Show for the Boom
• Negative Sentiment: Analysts describe Merck’s 2027 growth outlook as challenging, citing generic competition, weaker vaccine performance and slowing growth for Keytruda. These pressures could weigh on near-term results, despite the company’s expanding pipeline. Article: MRK’s 2027 Outlook Challenging, Long-Term Prospects Promising

Merck & Co., Inc. Stock Up 1.2%

Shares of NYSE:MRK opened at $148.49 on Tuesday. Merck & Co., Inc. has a 1 year low of $85.80 and a 1 year high of $156.92. The business has a 50 day simple moving average of $146.39 and a two-hundred day simple moving average of $127.82. The firm has a market capitalization of $366.34 billion, a PE ratio of 153.08, a price-to-earnings-growth ratio of 6.83 and a beta of 0.13. The company has a debt-to-equity ratio of 1.22, a current ratio of 1.32 and a quick ratio of 1.10.

Merck & Co., Inc. (NYSE:MRK) last released its earnings results on Thursday, October 29th. The company reported $2.49 EPS for the quarter, beating analysts’ consensus estimates of $2.09 by $0.40. Merck & Co., Inc. had a return on equity of 16.56% and a net margin of 3.64%. The firm had revenue of $18.09 billion for the quarter, compared to analysts’ expectations of $17.33 billion. During the same quarter in the prior year, the firm posted $2.58 earnings per share. The company’s quarterly revenue was up 4.7% on a year-over-year basis. On average, equities analysts predict that Merck & Co., Inc. will post 2.84 EPS for the current year.

Analyst Ratings Changes

Several research firms have recently weighed in on MRK. Barclays boosted their target price on Merck & Co., Inc. from $150.00 to $180.00 and gave the company an “overweight” rating in a research report on Monday, October 26th. HSBC raised their price target on Merck & Co., Inc. from $150.00 to $172.00 and gave the stock a “buy” rating in a research report on Thursday, September 10th. Wall Street Zen upgraded Merck & Co., Inc. from a “hold” rating to a “strong-buy” rating in a research report on Saturday. Royal Bank Of Canada dropped their price objective on shares of Merck & Co., Inc. from $145.00 to $140.00 and set a “sector perform” rating for the company in a research note on Friday, October 30th. Finally, Wells Fargo & Company boosted their price objective on shares of Merck & Co., Inc. from $150.00 to $170.00 and gave the company an “overweight” rating in a research report on Friday, September 4th. One research analyst has rated the stock with a Strong Buy rating, sixteen have assigned a Buy rating, eleven have assigned a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and a consensus target price of $155.74.

Insider Activity at Merck & Co., Inc.

In related news, EVP Chirfi Guindo sold 10,000 shares of the business’s stock in a transaction on Thursday, August 13th. The stock was sold at an average price of $135.00, for a total transaction of $1,350,000.00. Following the completion of the transaction, the executive vice president owned 36,613 shares in the company, valued at $4,942,755. The trade was a 21.45% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, EVP Jennifer Zachary sold 80,315 shares of the company’s stock in a transaction on Wednesday, August 12th. The shares were sold at an average price of $133.46, for a total value of $10,718,839.90. Following the completion of the transaction, the executive vice president directly owned 45,509 shares in the company, valued at $6,073,631.14. This trade represents a 63.83% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Insiders sold a total of 102,014 shares of company stock worth $13,608,779 in the last quarter. 0.17% of the stock is owned by company insiders.

Merck & Co., Inc. Company Profile

Merck & Co, Inc is a global pharmaceutical company that develops and markets prescription medicines, vaccines, biologic therapies and animal-health products. The company’s research and commercial activities span areas including oncology, infectious diseases, vaccines, cardiovascular disease and immunology. Its products include the cancer medicine Keytruda and the Gardasil vaccine.

Founded in the United States in 1891, Merck & Co became an independent company in 1917. It is headquartered in Rahway, New Jersey, and operates internationally.